New combo therapy aims to boost bladder cancer treatment before surgery

NCT ID NCT07440901

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding immunotherapy (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with muscle-invasive bladder cancer. About 30 participants will receive the combination therapy, and researchers will monitor how the tumor and immune system respond. The goal is to find better ways to predict and enhance treatment success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab combined with chemotherapy (GC regimen)
What this could lead to: If successful, this could lead to a more effective neoadjuvant treatment approach for muscle-invasive bladder cancer, potentially improving outcomes before surgery.
What could go wrong: This is an early exploratory study with only 30 participants, so results may not apply broadly. The combination therapy may also cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE-INVASIVE BLADDER CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.